公开(公告)号：US20190008830A1

公开(公告)日：2019-01-10

申请号：US16039098

申请日：2018-07-18

Applicant: Agency for Science, Technology and Research

Inventor： Motoichi Kurisawa ,  Yongvongsoontorn Nunnarpas ,  Jackie Y. YING ,  Joo Eun CHUNG ,  Ki Hyun BAE ,  Min-Han TAN ,  Esther LEE

IPC: A61K31/404 ,  C08G65/332 ,  C08G65/331 ,  A61K31/704 ,  A61K47/60 ,  C08L89/00 ,  C08L5/16 ,  C08L5/02 ,  C08L5/00 ,  C08L3/02 ,  C08L1/02

Abstract: The present invention relates to micellar nanocomplexes and a method of forming the same. The micellar nanocomplex comprises a micelle and an agent encapsulated within said micelle, where the micelle comprises a polymer-flavonoid conjugate, wherein said polymer is bonded to the B ring of said flavonoid. The micellar nanocomplex may have useful applications as a drug-delivery system.

公开(公告)号：US20190119721A1

公开(公告)日：2019-04-25

申请号：US15541295

申请日：2016-01-21

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Min-Han TAN ,  Igor CIMA

IPC: C12Q1/686 ,  C12Q1/6876 ,  C12Q1/6806

Abstract: A method of simultaneously analyzing RNA and DNA in a sample, the method comprising the step (a) contacting the sample with a reverse primer from a first primer pair directed to a target RNA region to effect reverse transcription of RNA into cDNA with a reverse transcriptase; (b) subsequently contacting the sample with (i) a forward primer from the first primer pair directed to a second cDNA region, (ii) a forward and a reverse primers from a second primer pair targeted to a DNA region, and (ii) a DNA polymerase to simultaneously amplify the target cDNA and target DNA region; and (c) analyzing the amplified target cDNA region and/or amplified target DNA region. Also encompassed are uses of the method to analyze gene expression and mutations, kits comprising primers, enzymes, buffers.

公开(公告)号：US20180073083A1

公开(公告)日：2018-03-15

申请号：US15557776

申请日：2016-03-14

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  Singapore Health Services Pte Ltd

Inventor： Min-Han TAN ,  Puay Hoon TAN ,  Wai Jin TAN ,  Igor CIMA

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12Q1/686 ,  C12Q2545/00 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57484 ,  G01N2800/52

Abstract: An in vitro method of determining the type of a fibroepithelial tumour of the breast in a biological sample is provided. The method comprises the steps of obtaining an expression profile of one or more genes selected from the group consisting of PRAME, ADH1 B, CTHRC1, NPTX2, NEFL, ABCA8, DAPL1, TP63_v2, COL17A1, GCNT2, CCL19, MMP3, FN1, TRERF1, TRIM29, TESC, KIF20A, UHRF1, HEPACAM2, APOD, SERHL2. KIF15, HOXD13, GAGE2B, CALML5, C2orf40, ADH1C, CYP1B1, SPAG11B, GRB7, UBE2C, SYNGAP1, TP63_v1, LAMB1, OR5P3, SPC25, SHISA2, SCARA5, LHX2, RORC, DPYSL4, CH25H, and CHST1 in a sample and determining the differential activity of the one or more genes relative to a control; correlating the differential activity of the one or more genes relative to the control to obtain a p-score; and determining the type of fibroepithelial tumour based on the p-score, wherein a p-score of less than 0.5 is indicative of a fibroadenoma and a p-score of 0.5 and above is indicative of phyllodes tumour. Particularly, the said method is exemplified using an expression profile of five genes comprising of PRAME, FN1, CCL19, ABCA8 and APOD. A method for managing the treatment of a subject with a fibroepithelial tumour of the breast is also provided as well as a kit when used in the methods of the present invention.

公开(公告)号：US20160251725A1

公开(公告)日：2016-09-01

申请号：US15026957

申请日：2014-10-03

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  SINGAPORE HEALTH SERVICES PTE LTD

Inventor： Min-Han TAN ,  Ying Hsia CHU ,  Johnathan LAI ,  Puay Hoon TAN

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: A method for determining the sensitivity of a patient with cancer to receptor tyrosine kinase inhibitor therapy is provided. The method comprising screening a nucleic acid sample to determine the identity of at least one single nucleotide polymorphism (SNP) genotype selected from the group consisting of rs1933437, rs1045642, rs1128503, rs2032582 and rs2231142 and any combination thereof; and determining the sensitivity of a patient with renal cancer to receptor tyrosine kinase inhibitor therapy based on the identity of the SNP genotype. The sensitivity is selected from one or more of neutropenia, diarrhea, tumor response, early toxicity-necessitated treatment termination, overall survival and progression-free survival.

Abstract translation: 提供了一种用于确定癌症患者对受体酪氨酸激酶抑制剂治疗的敏感性的方法。 该方法包括筛选核酸样品以确定选自由rs1933437，rs1045642，rs1128503，rs2032582和rs2231142及其任何组合组成的组的至少一个单核苷酸多态性（SNP）基因型的同一性; 并且基于SNP基因型的身份，确定患有肾癌的患者对受体酪氨酸激酶抑制剂治疗的敏感性。 灵敏度选自中性粒细胞减少，腹泻，肿瘤反应，早期毒性必需的治疗终止，总体存活和无进展生存中的一种或多种。